NOF Corporation Makes Strategic Minority Investment in Phosphorex

Ampersand Capital Partners Majority Recapitalizes Phosphorex

August 25, 2022

Healthcare Services

Ampersand Capital Partners completed a majority recapitalization of Phosphorex to provide growth capital enabling the company to build out a 30,000 sq. ft. facility and establish cGMP manufacturing capabilities for lipid nanoparticles, microspheres and other drug-delivery platforms. The investment positions Phosphorex to expand from development and analytical services into end-to-end CDMO manufacturing to better serve pharmaceutical and biotechnology clients.

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

Novopor Advanced Science Acquires FAR Chemical from CPS Performance Materials Group

January 23, 2026

Manufacturing

Novopor Advanced Science, a Bain Capital–backed performance chemicals and materials CDMO, has acquired FAR Chemical from CPS Performance Materials Group to expand its U.S. footprint and add capabilities in complex specialty chemistries. The deal integrates FAR Chemical's expertise in custom and hazardous specialty chemical manufacturing—serving electronics, aerospace & defense, and coatings/adhesives end markets—into the Novopor platform.

APNAR Pharma Acquires Aurex Laboratories

February 3, 2022

Pharmaceuticals

APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.

Foremark Performance Chemicals Acquires NexGen Chemical Technologies

May 16, 2023

Energy

Foremark Performance Chemicals, a portfolio company of SK Capital Partners, has acquired NexGen Chemical Technologies from Black Bay Energy Capital. The add-on acquisition expands Foremark's natural gas sweetening product portfolio, enables scale-up of NexGen's ScavGen 1014 manufacturing at Foremark's La Porte, Texas site, and broadens Foremark's geographic reach and customer base.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.